Adam J. Evans
Research Subjects
Adam J. Evans has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Edwin C. Everts
Department of Otolaryngology, Oregon Health & Science University, Portland, Oregon
2 shared publicationsGail M Clinton
2 shared publicationsJames I. Cohen
Department of Otolaryngology, Oregon Health & Science University, Portland, Oregon
2 shared publicationsJean-Louis K. Kouadio
Monsanto Co., 800 North Lindbergh Blvd., St. Louis, MO, United States
2 shared publicationsJeffrey A. Haas
Monsanto Co., 800 North Lindbergh Blvd., St. Louis, MO, United States
2 shared publicationsJeffrey E. McWilliams
Division of Hematology and Medical Oncology, Oregon Health & Science University, Mail Code L586, 3181 S.W. Sam Jackson Park Rd., Portland, Oregon 97201
2 shared publications
Latest Publications
- Open Access
- 24 February 2021
- Published by Wiley in Pest Management Science
- Vol. 77 (8) , 3727-3736
A new generation of Bt maize for control of fall armyworm (Spodoptera frugiperda)
BACKGROUND: The pyramided genetically modified maize (Zea mays [L.]) event MON 95379, expressing the Cry1B.868 and Cry1Da_7 proteins, was designed to protect against larval feeding damage by the fall armyworm, Spodoptera frugiperda (FAW). Here, we conducted laboratory, greenhouse, and field studies to assess the dose and field efficacy of MON 95379 against FAW and inform the development of insect resistance management plans.RESULTS: The Cry1B.868 and Cry1Da_7 proteins were active against susceptible FAW neonates in diet‐incorporation bioassays: median lethal concentration [LC50] (95% CI) = 62.8 (42.6–87.6) μg/ml diet for Cry1B.868 and 9.4 (5.3–18.6) μg/ml diet for Cry1Da_7. In laboratory leaf disc bioassays, MON 95379 maize and experimental maize lines expressing the individual components were effective in controlling susceptible FAW. In whole‐plant assays, MON 95379 controlled FAW resistant to the Cry1A.105 and Cry2Ab2 proteins. Likewise, under field conditions, MON 95379 maize expressing Cry1B.868 and Cry1Da_7 was highly effective at protecting plants against the larval feeding of FAW.CONCLUSIONS: The expression of Cry1B.868 and Cry1Da_7 in MON 95379 consistently protected maize plants against larval feeding by FAW and represents an alternative to manage trait resistance issues in South America. © 2021 Bayer Crop Science‐US. Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
- 24 February 2021
- Published by Wiley in Pest Management Science
- Vol. 77 (8) , 3727-3736
Open AccessA new generation of Bt maize for control of fall armyworm (Spodoptera frugiperda)
BACKGROUND: The pyramided genetically modified maize (Zea mays [L.]) event MON 95379, expressing the Cry1B.868 and Cry1Da_7 proteins, was designed to protect against larval feeding damage by the fall armyworm, Spodoptera frugiperda (FAW). Here, we conducted laboratory, greenhouse, and field studies to assess the dose and field efficacy of MON 95379 against FAW and inform the development of insect resistance management plans.RESULTS: The Cry1B.868 and Cry1Da_7 proteins were active against susceptible FAW neonates in diet‐incorporation bioassays: median lethal concentration [LC50] (95% CI) = 62.8 (42.6–87.6) μg/ml diet for Cry1B.868 and 9.4 (5.3–18.6) μg/ml diet for Cry1Da_7. In laboratory leaf disc bioassays, MON 95379 maize and experimental maize lines expressing the individual components were effective in controlling susceptible FAW. In whole‐plant assays, MON 95379 controlled FAW resistant to the Cry1A.105 and Cry2Ab2 proteins. Likewise, under field conditions, MON 95379 maize expressing Cry1B.868 and Cry1Da_7 was highly effective at protecting plants against the larval feeding of FAW.CONCLUSIONS: The expression of Cry1B.868 and Cry1Da_7 in MON 95379 consistently protected maize plants against larval feeding by FAW and represents an alternative to manage trait resistance issues in South America. © 2021 Bayer Crop Science‐US. Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
- 1 June 2016
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 600, 1-11
Mechanistic insights into the first Lygus-active β-pore forming protein
- 1 June 2016
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 600, 1-11
Mechanistic insights into the first Lygus-active β-pore forming protein
- 24 May 2004
- Published by Wiley in FEBS Letters
- Vol. 568 (1-3) , 163-166
Receptor binding specificities of Herstatin and its intron 8‐encoded domain
Retention of intron 8 in alternative HER-2 mRNA generates an inhibitory secreted ligand, Herstatin, with a novel receptor-binding domain (RBD) encoded by the intron. This study examines binding interactions with several receptors and investigates sequence variations in intron 8. The RBD, expressed as a peptide, binds at nM concentrations to HER-2, the EGFR, ΔEGFR, HER-4 and to the IGF-1 receptor, but not to HER-3 nor to the FGF-3 receptor, whereas a rare mutation in the RBD (Arg to Ile) eliminates receptor binding. The full-length Herstatin binds with 3–4-fold higher affinity than its RBD, but with ∼10-fold lower affinity to the IGF-IR. Sequence conservation in rhesus monkey but not in rat suggests that intron 8 recently diverged as a receptor-binding module critical for the function of Herstatin
- 24 May 2004
- Published by Wiley in FEBS Letters
- Vol. 568 (1-3) , 163-166
Receptor binding specificities of Herstatin and its intron 8‐encoded domain
Retention of intron 8 in alternative HER-2 mRNA generates an inhibitory secreted ligand, Herstatin, with a novel receptor-binding domain (RBD) encoded by the intron. This study examines binding interactions with several receptors and investigates sequence variations in intron 8. The RBD, expressed as a peptide, binds at nM concentrations to HER-2, the EGFR, ΔEGFR, HER-4 and to the IGF-1 receptor, but not to HER-3 nor to the FGF-3 receptor, whereas a rare mutation in the RBD (Arg to Ile) eliminates receptor binding. The full-length Herstatin binds with 3–4-fold higher affinity than its RBD, but with ∼10-fold lower affinity to the IGF-IR. Sequence conservation in rhesus monkey but not in rat suggests that intron 8 recently diverged as a receptor-binding module critical for the function of Herstatin
- 6 November 2003
- Published by Springer Nature in Oncogene
- Vol. 22 (50) , 8178-8186
Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2
Ligands of the ErbB family of receptors and estrogens control the proliferation of breast cancer cells. Overexpression of human EGF receptor HER-2 (erbB2) leads to amplified heregulin (HRG) signaling, promoting more aggressive breast cancer that is nonresponsive to estrogen and the antiestrogenic drug tamoxifen. Herstatin (Hst), a secreted HER-2 gene product, binds to the HER-2 receptor ectodomain blocking receptor activation. The aim of this study was to investigate the impact of this HER-2 inhibitor on HRG-induced signaling, proliferation, and sensitivity to tamoxifen in breast cancer cells with and without HER-2 overexpression. The expression of Hst in MCF7 cells eliminated HRG signaling through both mitogen-activated protein kinase and Akt pathways and prevented HRG-mediated proliferation. The loss in signaling corresponded to downregulation of the HRG receptors, HER-3 and HER-4, whereas HER-2 overexpression strongly stimulated the levels of both HRG receptors. Although Hst blocked HRG signaling in both parental and HER-2 transfected cells, it enhanced sensitivity to tamoxifen only in the MCF7 cells that overexpressed HER-2. To evaluate further the efficacy of Hst as an anticancer agent, His-tagged Hst was expressed in transfected insect cells, purified, and added to the breast cancer cells. As in the transfected cells, purified Hst inhibited HER-3 levels and suppressed HRG-induced proliferation of MCF7 and BT474 breast cancer cells. In contrast, the HER-2 monoclonal antibody, herceptin, downregulated HER-2, but not HER-3. These results suggest the potential use of Hst against HRG-mediated growth of breast cancers with high and low levels of HER-2 and against tamoxifen resistance in HER-2 overexpressing breast cancer.
- 6 November 2003
- Published by Springer Nature in Oncogene
- Vol. 22 (50) , 8178-8186
Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2
Ligands of the ErbB family of receptors and estrogens control the proliferation of breast cancer cells. Overexpression of human EGF receptor HER-2 (erbB2) leads to amplified heregulin (HRG) signaling, promoting more aggressive breast cancer that is nonresponsive to estrogen and the antiestrogenic drug tamoxifen. Herstatin (Hst), a secreted HER-2 gene product, binds to the HER-2 receptor ectodomain blocking receptor activation. The aim of this study was to investigate the impact of this HER-2 inhibitor on HRG-induced signaling, proliferation, and sensitivity to tamoxifen in breast cancer cells with and without HER-2 overexpression. The expression of Hst in MCF7 cells eliminated HRG signaling through both mitogen-activated protein kinase and Akt pathways and prevented HRG-mediated proliferation. The loss in signaling corresponded to downregulation of the HRG receptors, HER-3 and HER-4, whereas HER-2 overexpression strongly stimulated the levels of both HRG receptors. Although Hst blocked HRG signaling in both parental and HER-2 transfected cells, it enhanced sensitivity to tamoxifen only in the MCF7 cells that overexpressed HER-2. To evaluate further the efficacy of Hst as an anticancer agent, His-tagged Hst was expressed in transfected insect cells, purified, and added to the breast cancer cells. As in the transfected cells, purified Hst inhibited HER-3 levels and suppressed HRG-induced proliferation of MCF7 and BT474 breast cancer cells. In contrast, the HER-2 monoclonal antibody, herceptin, downregulated HER-2, but not HER-3. These results suggest the potential use of Hst against HRG-mediated growth of breast cancers with high and low levels of HER-2 and against tamoxifen resistance in HER-2 overexpressing breast cancer.
- 23 September 2003
- Published by Wiley in Head & Neck
- Vol. 26 (1) , 63-70
Polymorphisms of GSTT1 and related genes in head and neck cancer risk
- 23 September 2003
- Published by Wiley in Head & Neck
- Vol. 26 (1) , 63-70
Polymorphisms of GSTT1 and related genes in head and neck cancer risk
- 1 February 2002
- Vol. 8 (2) , 347-53
NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.
The full-length receptor p185HER-2 undergoes a metalloprotease-dependent cleavage producing a membrane-associated fragment (p95HER-2) in cultured breast cancer cells. P95HER-2 has potentially enhanced signaling activity, but its expression and role in human breast cancer is poorly characterized. The purpose of this project was to characterize the expression of p95HER-2 in primary breast cancers and nodal metastasis, and to study association with clinicopathological factors. P95HER-2 and p185HER-2 were examined in 337 primary breast tumors and 81 metastatic lymph nodes by Western blot analysis, and tested for associations with other clinicopathological factors. P95HER-2 was present in 20.9% of primary tumors from node-negative patients, in 29.1% from patients with one to three metastatic nodes, and in 36.7% from patients with four or more metastatic nodes (P = 0.027). Whereas p185HER-2 overexpression was unrelated to nodal disease (P = 0.63), the odds of lymph node metastasis were enhanced 2.9-fold by the presence of p95HER-2 (48.8% of node-negative versus 73.5% of node-positive patients; P = 0.03; odds ratio = 2.9). P95HER-2 was more frequent in metastatic lymph nodes than in primary tumors (45.7% versus 26.7%; P = 0.0009), whereas p185HER-2 overexpression was similar in both (22.3% versus 23.5%; P = 0.933). P95HER-2 did not significantly correlate with patient age, tumor size, stage, histotype, or hormone receptor status. P95HER-2 in primary tumors was related to extent of lymph node involvement and was enhanced in nodal tissue suggesting an important role as a marker or cause in breast cancer metastasis. Examination of the prognostic value of p95HER-2 in breast cancer and its coexpression with metalloprotease activity seem warranted.
- 1 February 2002
- Vol. 8 (2) , 347-53
NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.
The full-length receptor p185HER-2 undergoes a metalloprotease-dependent cleavage producing a membrane-associated fragment (p95HER-2) in cultured breast cancer cells. P95HER-2 has potentially enhanced signaling activity, but its expression and role in human breast cancer is poorly characterized. The purpose of this project was to characterize the expression of p95HER-2 in primary breast cancers and nodal metastasis, and to study association with clinicopathological factors. P95HER-2 and p185HER-2 were examined in 337 primary breast tumors and 81 metastatic lymph nodes by Western blot analysis, and tested for associations with other clinicopathological factors. P95HER-2 was present in 20.9% of primary tumors from node-negative patients, in 29.1% from patients with one to three metastatic nodes, and in 36.7% from patients with four or more metastatic nodes (P = 0.027). Whereas p185HER-2 overexpression was unrelated to nodal disease (P = 0.63), the odds of lymph node metastasis were enhanced 2.9-fold by the presence of p95HER-2 (48.8% of node-negative versus 73.5% of node-positive patients; P = 0.03; odds ratio = 2.9). P95HER-2 was more frequent in metastatic lymph nodes than in primary tumors (45.7% versus 26.7%; P = 0.0009), whereas p185HER-2 overexpression was similar in both (22.3% versus 23.5%; P = 0.933). P95HER-2 did not significantly correlate with patient age, tumor size, stage, histotype, or hormone receptor status. P95HER-2 in primary tumors was related to extent of lymph node involvement and was enhanced in nodal tissue suggesting an important role as a marker or cause in breast cancer metastasis. Examination of the prognostic value of p95HER-2 in breast cancer and its coexpression with metalloprotease activity seem warranted.
- 19 November 2001
- Published by Wiley in The Prostate
- Vol. 49 (4) , 263-266
Association of codon 72 polymorphism of p53 with lower prostate cancer risk
Background: A common germline polymorphism of p53 produces a protein with an Arg to Pro change at codon 72. This Pro variant has altered biochemical properties suggesting altered cancer susceptibility.Methods: A case control study with 115 men with prostate cancer and 181 community control male subjects was conducted. Demographics, family history of cancer, and blood were obtained. Codon 72 genotypes were determined using PCR.Results: The Pro/Pro genotype was associated with a markedly lower risk of prostate cancer (OR = 0.23, CI = 0.07–0.79, P = 0.012). Similar reduction in risk was observed when the analysis was limited to Caucasian subjects (86% of total). Reduction in risk remained significant in a logistic regression model after correcting for age and family history of prostate cancer (OR = 0.14, CI = 0.03–0.71, P = 0.017).Conclusions: Men with the p53 codon 72 Pro/Pro genotype appear to be at reduced risk of prostate cancer. Prostate 49:263–266, 2001.
- 19 November 2001
- Published by Wiley in The Prostate
- Vol. 49 (4) , 263-266
Association of codon 72 polymorphism of p53 with lower prostate cancer risk
Background: A common germline polymorphism of p53 produces a protein with an Arg to Pro change at codon 72. This Pro variant has altered biochemical properties suggesting altered cancer susceptibility.Methods: A case control study with 115 men with prostate cancer and 181 community control male subjects was conducted. Demographics, family history of cancer, and blood were obtained. Codon 72 genotypes were determined using PCR.Results: The Pro/Pro genotype was associated with a markedly lower risk of prostate cancer (OR = 0.23, CI = 0.07–0.79, P = 0.012). Similar reduction in risk was observed when the analysis was limited to Caucasian subjects (86% of total). Reduction in risk remained significant in a logistic regression model after correcting for age and family history of prostate cancer (OR = 0.14, CI = 0.03–0.71, P = 0.017).Conclusions: Men with the p53 codon 72 Pro/Pro genotype appear to be at reduced risk of prostate cancer. Prostate 49:263–266, 2001.
- 8 August 2000
- Published by Wiley in Head & Neck
- Vol. 22 (6) , 609-617
Genetic polymorphisms in head and neck cancer risk
Objective To assess whether genetic polymorphisms implicated as risk factors for other tobacco-associated malignancies are associated with altered risk of head and neck squamous cell carcinoma. Design Case-control study. Subjects One hundred sixty patients with head and neck squamous cell carcinoma recruited from a university-based head and neck oncology clinic and 149 population-based controls. Methods Genotyping of the CYP1A1 (Ile462Val), GSTM1 (null), GSTP1 (Ile105Val), GSTT1 (null), and P53 (Arg72Pro) genes was performed by polymerase chain reaction–based techniques on DNA prepared from peripheral blood. In addition, a questionnaire was used to collect demographic information from each subject. Results Cases were significantly older (p < .0001) and had significantly greater tobacco use (p < .0001) and were more likely to be male (p < .0001) than were control subjects, thus confirming known risk factors for this disease. When cases and controls were compared by simple chi-square analysis, only the frequency of CYP1A1 (Ile462Val) polymorphism was significantly different between cases and controls (OR = .42; 95% CI = .18–.99; p < .04). However, with a logistic regression model to control for known risk factors, we were unable to demonstrate a significant association with head and neck cancer for any of the polymorphisms tested, including CYP1A1. Conclusions This population fails to identify a relationship between the above-mentioned polymorphisms and head and neck cancer. © 2000 John Wiley & Sons, Inc. Head Neck 22: 609–617, 2000.
- 8 August 2000
- Published by Wiley in Head & Neck
- Vol. 22 (6) , 609-617
Genetic polymorphisms in head and neck cancer risk
Objective To assess whether genetic polymorphisms implicated as risk factors for other tobacco-associated malignancies are associated with altered risk of head and neck squamous cell carcinoma. Design Case-control study. Subjects One hundred sixty patients with head and neck squamous cell carcinoma recruited from a university-based head and neck oncology clinic and 149 population-based controls. Methods Genotyping of the CYP1A1 (Ile462Val), GSTM1 (null), GSTP1 (Ile105Val), GSTT1 (null), and P53 (Arg72Pro) genes was performed by polymerase chain reaction–based techniques on DNA prepared from peripheral blood. In addition, a questionnaire was used to collect demographic information from each subject. Results Cases were significantly older (p < .0001) and had significantly greater tobacco use (p < .0001) and were more likely to be male (p < .0001) than were control subjects, thus confirming known risk factors for this disease. When cases and controls were compared by simple chi-square analysis, only the frequency of CYP1A1 (Ile462Val) polymorphism was significantly different between cases and controls (OR = .42; 95% CI = .18–.99; p < .04). However, with a logistic regression model to control for known risk factors, we were unable to demonstrate a significant association with head and neck cancer for any of the polymorphisms tested, including CYP1A1. Conclusions This population fails to identify a relationship between the above-mentioned polymorphisms and head and neck cancer. © 2000 John Wiley & Sons, Inc. Head Neck 22: 609–617, 2000.